35 results about "Anticarcinogenic Effect" patented technology

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.

The present invention relates to a peptide binding to OTUB1 and a use thereof. A peptide of a specific sequence having the property of binding to OTUB1 is observed to exhibit an anticancer effect on cancer cells without affecting the cell growth of normal cells, and thus can be usefully used as a composition for preventing, treating, or alleviating cancer diseases.

The invention relates to a composition containing selenium gluconate and application of the composition in preparation of anti-cancer drugs. The composition comprises a shiitake mushroom extract, a chicory extract and selenium gluconate. Wherein the selenium gluconate is selenium salt of gluconic acid, has an anti-cancer effect, but is easy to generate side effects when being independently used; according to the invention, the mushroom extract, the chicory extract and the selenium gluconate are combined for use, so that the killing power of the composition on cancer cells can be synergistically improved, the immunity can be remarkably improved, the related side effects can be effectively reduced, and the damage to normal cells can be reduced.

The present invention relates to a methionine sulfoxide reductase B1 inhibitor and an anticancer composition comprising same. More specifically, the present invention relates to 4-[3-(4-ethylphenyl)-5-(4-hydroxyphenyl) -4,5-dihydro -1 H-pyrazol-1-yl]benzene-1-sulfonamide or 6-chloro-10-(4-ethylphenyl)-4-hydroxypyrimido[4,5-b]quinolin-2(10H)-one, which is a MsrB1 inhibitor, and an anticancer composition comprising same. The MsrB1 inhibitor of the present invention has been confirmed to inhibit differentiation into tumor-friendly M2 macrophages and to suppress tumor growth. In addition, the MsrB1 inhibitor of the present invention was found to exhibit anticancer effects through immune regulation within the tumor microenvironment, and thus can be usefully applied as a composition for cancer treatment.

Provided are compositions and methods that include use of micro-RNAs and mimics of the micro-RNAs for treating cancer. Specific ratios of micro-RNAs that have enhanced anti-cancer properties for treating prostate, bladder, and head and neck cancer are provided. The micro-RNAs are conjugated to nanoparticles configured so that exposure to light releases the micro-RNAs from the nanoparticles, thereby allowing the microRNAs to elicit anti-cancer effects.

The present invention pertains to a composition, containing aripiprazole as an active ingredient, for enhancing the anticancer effect of a RAF inhibitor. More specifically, the present invention pertains to a composition for enhancing the anticancer effect of the RAF inhibitor, wherein the composition can treat cancer by acting as an agent for enhancing the anticancer effect of the RAF inhibitor when used in combination therapy with aripiprazole. Administering an effective amount of aripiprazole according to the present invention in combination with the RAF inhibitor is highly effective in enhancing the anticancer effect of the RAF inhibitor, such as by inducing cancer cell death, and thus the composition can be advantageously used as an agent for enhancing the anticancer effect of the RAF inhibitor.

The present invention relates to: an antibody targeting a mutation of KRAS as an intracellular oncoprotein; or a fusion protein in which a cancer cell-penetrating peptide is linked to a single-chain variable fragment of the antibody by a genetic expression method or a chemical bonding method; and a tumor therapeutic use thereof. The fusion protein thus produced has the benefit of maximizing an anti-tumor or anticancer effect of the antibody or the single-chain variable fragment of the antibody targeting an intracellular oncoprotein or an oncomutant protein by effectively invading tumor cells.

The present invention addresses the problem of developing a drug for inhibiting the DNA damage restoration mechanism in a cancer which does not have a mutation in BRCA 1 / 2 and in which homologous recombination repair functions normally.　The inventors of the present invention have clarified that cell death can be induced by inhibiting PARP functions and mitochondrial respiration functions in cells, and indicated that the problem can be solved. In other words, the present invention provides: a method for inducing cell death by inhibiting PARP functions and mitochondrial respiration functions in cells; and a pharmaceutical composition for treating cancer, the pharmaceutical composition containing a PARP inhibitor and a mitochondrial respiration inhibitor.

This invention discloses an epigenetic drug targeting lncRNA-PSF interaction, its composition, and its application. First, this invention synthesizes an epigenetic drug targeting lncRNA-PSF interaction as shown in formula (I) or formula (II). Compared with existing technologies, the epigenetic drugs shown in formulas (I) and (II) can inhibit lncRNA-PSF interaction, alter the cell cycle by increasing the expression of p27 and p53 proteins, arrest cancer cells in the G2 / M phase, and thus exert an anti-cancer effect. When the epigenetic drugs shown in formulas (I) and (II) are used in combination with immunosuppressants, they can enhance the effect of immunosuppressants, increase antigen presentation by cancer cells, and reduce their immune escape, thus becoming a novel anti-cancer sensitization strategy.

The invention discloses a selenium vitamin E capsule composition for resisting cancer and assisting in protecting chemical liver injury, and belongs to the technical field of health food. The composition is prepared from active ingredients and pharmaceutic adjuvants, wherein the active ingredients comprise L-selenium-methyl selenocysteine, vitamin E, vitamin C and vitamin B3. All the active ingredients generate a synergistic effect through scientific proportioning, so that the composition not only can effectively inhibit cancer cell proliferation and play an anti-cancer role, but also can relieve damage of chemical toxins to the liver through a strong anti-oxidation mechanism and assist in protecting the liver function. The product disclosed by the invention is high in bioavailability and good in safety, and has remarkable beneficial effects.

The invention belongs to the technical field of polypeptide drugs, and particularly relates to a series of polypeptides with an anti-cancer effect and application thereof. According to the invention, Rink amide MBHA amino resin is used as a solid phase carrier, modification is carried out according to an amino acid sequence of a template polypeptide Hymenochirin-1Pa (H-0): Ac-LKLSPKTKDTLKKVLKGAIKGAIAIASAMA-NH2, and on the basis of retaining key amino acid residues, original amino acids are replaced by R8 and S5 at the positions of i and i + 7 amino acids, so that the target stapling peptide is obtained. Compared with a template polypeptide H-0, the obtained stapled peptide has the advantage that the anti-tumor activity on human liver cancer cells Huh7, human non-small cell lung cancer cells A549, glioma cells U87 and colon cancer cells T84 can be obviously improved.

The present invention relates to a highly active transposase protein for a transposon system and its uses. By improving the activity of the transposase, genes can be delivered effectively, which can be useful for developing genome-modified cell lines that express various genes. In addition, when T cells are transformed using the highly active transposase of the present invention, cytotoxic T cells (CD8) that have anti-cancer effects can be generated. + The proportion of T cells increases, and T cells persist in the body. CM (Central memory T cell), T SCM Since the proportion of memory-type T cells (stem cell-like memory T cells) increased, it is expected that TCR-T cells and CAR-T cells with good in vivo persistence can be produced using the transposon system of the present invention.

This invention discloses the application of gluconate compounds in the preparation of drugs for the prevention and treatment of ovarian cancer. The gluconate compounds include at least one of sodium gluconate, potassium gluconate, calcium gluconate, and zinc gluconate. The invention also discloses the application of gluconate compounds in the preparation of inhibitors of the interaction between TMEM87A protein and CHP1 protein. This invention is the first to discover and demonstrate that gluconate compounds possess significant anti-ovarian cancer activity, effectively inhibiting the proliferation and metastasis of ovarian cancer cells. It also reveals for the first time a novel anti-cancer mechanism by which sodium gluconate directly binds to TMEM87A protein and disrupts the functional complex formed between TMEM87A and CHP1 protein. This invention overcomes the technical prejudice commonly held by those skilled in the art that gluconates are merely nutritional supplements or chelating agents, providing a novel, safe, and widely available class of candidate drugs for the treatment of ovarian cancer.

The present invention relates to an anticancer composition comprising *Jeonho* as an active ingredient. When using the composition, an anticancer composition capable of exhibiting an anticancer effect by inducing apoptosis of cancer cells and inhibiting cell proliferation or colony formation of cancer cells can be provided. By including the composition, an anticancer pharmaceutical composition and an anticancer functional food composition without the problem of side effects can be provided.

The invention describes peptides with anticancer activity and exhibiting antagonistic activity against CD133 protein, which were obtained and designed by means of computer tools, evaluating physicochemical parameters of flexibility, hydrophilicity, hydrophobicity, antigenicity and total charge as described herein, in addition to the modeling of the protein, which allowed selecting 4 regions with the appropriate characteristics. After modeling the selected peptides, CD133 peptide-protein molecular docking was performed, where stable interactions were observed, even showing hydrogen bonds. Finally, the peptides of the invention showed anticancer effects against several cancer cell lines, including cancer cells resistant to conventional treatments such as triple negative breast cancer cells.

This invention relates to a novel strain of Prevotella merde immunoactis and its uses. The inventors have confirmed that the novel strain of Prevotella merde immunoactis (deposit number: KCTC 14922BP) not only increases T cell proliferation, increases T cell IFN-γ secretion, increases the expression or activity level of IFN-γ or Cxcl9, and decreases the expression or activity level of Ccl22, but also enhances the anticancer effect of immune checkpoint inhibitors. Therefore, the novel strain of Prevotella merde immunoactis or its culture medium is expected to be useful for immune enhancement and enhancing the anticancer effect of immune checkpoint inhibitors.

The invention relates to the technical field of biological medicine, in particular to a gene recombination cell exosome and application thereof in preparation of anti-cancer drugs. The gene recombinant cell exosome is extracted from an IL15K562 cell culture supernatant by the following method, and the method comprises the following steps: (1) collecting the IL15K562 cell culture supernatant, and centrifuging to remove cell debris; (2) adding a treatment reagent, uniformly mixing, and incubating for 6-20 hours; and (3) centrifuging to obtain a precipitate, further suspending the precipitate in a buffer solution, and centrifuging again to obtain the gene recombinant cell exosome. Researches show that the gene recombinant cell exosome prepared from the IL15K562 cell culture supernatant by the method disclosed by the invention has a remarkable anti-cancer effect; therefore, the compound has important application value when being used as an active ingredient for preparing the anti-cancer drugs.

Lymphoma is a group of cancers that originate This thesis investigates the antioxidant and anticancer effects of wild milk thistle extracts on lymphocytes. The seed extract (PEL) showed primary effusion. Wild artichoke with ethanol has the highest concentration of phenolic and flavonoid compounds, giving it the strongest activity. DPPH is an antioxidant with a 97.4% effectiveness rating according to testing. The biological evidence that MTT extracts clearly tested BC3 PEL cancer cells inhibit cell proliferation. In a manner independent of dose or time. The results suggest that the seeds and leaves of milk thistle may act as natural antioxidants with potential antiproliferative properties.

The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

This invention provides the application of ginkgo biloba extract enhancing VS4718 or ponatinib in the anti-progression of esophageal squamous cell carcinoma. This invention discovers that ginkgo biloba extract can enhance the inhibitory effects of VS4718 or ponatinib on the growth and invasion of esophageal squamous cell carcinoma cells; ginkgo biloba extract sensitizes the inhibitory effect of VS4718 or ponatinib on the glycolipid metabolism of tumor cells; and the combined use of ginkgo biloba extract with VS4718 or ponatinib produces a synergistic anti-cancer effect.

The application discloses application of a liquid fermentation product of a cryptoporus symbiotic bacteria in preparation of an anticancer drug and belongs to the technical field of cell biology. The cryptoporus symbiotic bacteria is Trichoderma stromaticum, which was preserved in the China General Microbiological Culture Collection Center on November 8, 2023, has a preservation number of CGMCC No. 40914 and a preservation address of No. 3, Institute of Microbiology, Chinese Academy of Sciences, Xiliujiaobei, Chaoyang District, Beijing. The liquid fermentation product of the cryptoporus symbiotic bacteria provided in the application has good biological activity, can inhibit the growth of tumors and has a good anticancer effect on lung cancer cells. The application provides a theoretical basis for the liquid fermentation product of the cryptoporus symbiotic bacteria as an antitumor drug.

The present disclosure relates to methods of treating patients having liver cancer by performing a genome-targeting technique. It is based, at least in part, on the discovery that a genome editing technique that specifically targets genomic mutations can induce cell death in a cancer cell, e.g., a hepatocellular cancer cell, having the genomic gene. The present disclosure provides methods for treating cancer patients that include performing a genome editing technique targeting a genomic mutation present within one or more cells of a subject to produce an anti-cancer effect.

Provided is a cancer-associated fibroblast inhibitor, particularly a cancer-associated fibroblast inhibitor capable of enhancing the anticancer effect of an anticancer agent. A cancer-associated fibroblast inhibitor containing a PDGFR inhibitor.

The present invention relates to a compound comprising a cisplatin component and a eugenol component. The present invention further relates to a synthesis method of said compound, pharmaceutical compositions comprising the compound and its medical uses. The present invention further relates to a method of treatment of cancer.

This invention relates to a selectively cancer-targeting Salmonella strain for treating cancer, and compositions comprising said strain for the prevention or treatment of cancer. In particular, the Salmonella strain of this invention has tumor-inhibiting effects but exhibits significantly low viability in normal organs, thus potentially possessing significant anticancer activity compared to conventional inventions.

This invention belongs to the field of pharmaceutical technology and discloses the inhibitory effects and mechanisms of action of sclerotinib on lung cancer cells, cervical cancer cells, and ovarian cancer cells. Compared with the currently available broad-spectrum antitumor drug fluorouracil, sclerotinib exhibits superior antitumor properties. In-depth research revealed that sclerotinib acts on the novel protein STAT3 in cancer treatment, inhibiting STAT3 phosphorylation and preventing phosphonate-modified protein dimers from entering the cell nucleus to initiate transcription. Furthermore, sclerotinib inhibits the downstream anti-apoptotic protein BCL-2 of STAT3, synergistically inhibiting tumor cell proliferation. In this study, based on the half-maximal inhibitory concentration (IC50) results of sclerotinib against lung cancer cells A549, cervical cancer cells HeLa, and ovarian cancer cells A2780, we directly verified the anticancer target of sclerotinib through experiments, elucidated its anticancer mechanism, and provided theoretical and experimental basis for its entry into preclinical and clinical trials.

Provided is a method of preventing or treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of siRNA as an active ingredient, wherein the composition significantly inhibits the cell proliferation effect of colorectal cancer or pancreatic cancer, thereby it has an excellent anticancer effect, and it reduces the expression level of KRAS mRNA; the composition also maintains the body weight of an individual even while reducing the size and weight of a tumor, and thus can be effectively used as an excellent anticancer therapeutic agent.